Dashboard
Manage Tickers

VOR Vor Biopharma Inc.

Nasdaq vorbio.com


$ 9.81 $ -0.25 (-2.51 %)    

Thursday, 13-Nov-2025 19:58:16 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 608.59 $ -9.26 (-1.5 %)
DIA $ 475.50 $ -6.59 (-1.37 %)
SPY $ 672.57 $ -8.41 (-1.24 %)
TLT $ 89.38 $ -0.42 (-0.46 %)
GLD $ 384.40 $ -4.31 (-1.11 %)
$ 9.75
$ 9.96
$ 9.50 x 25
$ 10.40 x 500
-- - --
$ 2.62 - $ 65.80
869,200
na
101.5M
$ 1.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-20-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-20-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-23-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-14-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 03-25-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

update-vor-biopharma-q3-adj-eps-333-misses-325-estimate
UPDATE: Vor Biopharma Q3 Adj. EPS $(3.33) ...
11/14/2025 04:27:55

Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(3.33) per share which missed the analyst consensus estimate of $(3.25...

vor-biopharma-q3-eps-12163-may-not-compare-to-332-estimate
Vor Biopharma Q3 EPS $(121.63) May Not Com...
11/13/2025 21:33:26

dow-gains-more-than-300-points-energy-vault-holdings-shares-jump
Dow Gains More Than 300 Points; Energy Vau...
11/11/2025 17:17:04

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
11/11/2025 17:09:17

vor-biopharma-secures-100-million-offering-after-reporting-efficacy-in-kidney-disease-trial
Vor Biopharma Secures $100 Million Offerin...
11/11/2025 14:43:16

Vor Biopharma prices $100 million share offering as partner RemeGen reports strong Phase 3 results for telitacicept in IgA neph...

us-stocks-mixed-sea-shares-gain-after-q3-results
US Stocks Mixed; Sea Shares Gain After Q3 ...
11/11/2025 14:40:54

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
11/11/2025 12:07:21

why-rocket-lab-shares-are-trading-higher-by-over-9-here-are-20-stocks-moving-premarket
Why Rocket Lab Shares Are Trading Higher B...
11/11/2025 10:55:19

reported-earlier-vor-bio-prices-100m-public-offering-of-10m-shares-of-common-stock-at-10-per-share
Reported Earlier, Vor Bio Prices $100M Pub...
11/11/2025 07:34:21

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
11/10/2025 21:07:39

vor-biopharma-launches-100m-common-stock-offering
Vor Biopharma Launches $100M Common Stock ...
11/10/2025 21:03:30

Vor Biopharma Inc. (Nasdaq: VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of a...

reported-saturday-vor-bio-phase-3-study-in-china-shows-telitacicept-achieved-primary-endpoint-of-reducing-proteinuria-in-iga-nephropathy-with-significant-kidney-function-stabilization-and-favorable-safety-profile
Reported Saturday, Vor Bio Phase 3 Study I...
11/10/2025 09:02:35

Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in...

vor-bio-announced-telitacicept-achieved-primary-endpoint-of-reducing-proteinuria-in-stage-a-of-phase-3-clinical-study-for-iga-nephropathy-in-china-statistically-significant-benefits-also-achieved-across-all-key-secondary-endpoints
Vor Bio Announced Telitacicept Achieved Pr...
11/08/2025 16:55:23

Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in...

hc-wainwright--co-maintains-buy-on-vor-biopharma-raises-price-target-to-52
HC Wainwright & Co. Maintains Buy on Vor B...
10/29/2025 17:36:05

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Vor Biopharma (NASDAQ:VOR) with a Buy and raises the price ...

vor-bios-collaborator-remegen-presents-48-week-open-label-extension-data-from-phase-3-study-in-china-evaluating-telitacicept-in-patients-with-gmg-at-aanem-annual-meeting
Vor Bio's Collaborator, RemeGen, Presents ...
10/29/2025 15:03:43

Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms100% of patients ...

vor-bio-to-present-48-week-phase-3-clinical-study-data-in-china-for-telitacicept-in-primary-sjogrens-disease-on-oct-28
Vor Bio To Present 48-Week, Phase 3 Clinic...
10/22/2025 20:31:53

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced toda...

vor-bio-to-present-clinical-data-from-stage-a-of-a-phase-3-study-in-china-evaluating-telitacicept-in-adults-with-iga-nephropathy-at-the-american-society-of-nephrologys-kidney-week-2025-november-59-in-houston-texas
Vor Bio To Present Clinical Data From Stag...
10/17/2025 12:03:01

Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced...

novartis-strengthens-kidney-disease-pipeline-with-promising-data
Novartis Strengthens Kidney Disease Pipeli...
10/16/2025 14:50:29

Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings...

vor-bio-announces-publication-of-results-from-phase-3-study-in-china-evaluating-telitacicept-in-sle-sponsored-by-collaborator-remegen-in-new-england-journal-of-medicine
Vor Bio Announces Publication Of Results F...
10/16/2025 12:04:14

Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients respondi...

baird-upgrades-vor-biopharma-to-outperform-raises-price-target-to-64
Baird Upgrades Vor Biopharma to Outperform...
10/15/2025 10:38:23

Baird analyst Jack Allen upgrades Vor Biopharma (NASDAQ:VOR) from Neutral to Outperform and raises the price target from $2...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION